What Factors Propelled The Growth Of The Epithelial Ovarian Cancer Market In The Past?
The epithelial ovarian cancer market has seen considerable growth due to a variety of factors.
• The market size for Epithelial Ovarian Cancer has seen a rapid expansion in the past few years. Forecasts predict an increase from $2.08 billion in 2024 to $2.42 billion in 2025, maintaining a compound annual growth rate (CAGR) of 16.5%.
Factors such as increasing interest in customized cancer therapies, growth in worldwide healthcare spending, and the escalating demand for less invasive surgical options have all contributed to this historical growth. Other contributing factors include an increased number of ovarian cancer survivors, heightened interest in gene therapies, and a rising demand for palliative care services.
What Is the Forecasted Market Size and Growth Rate for The Epithelial Ovarian Cancer Market?
The epithelial ovarian cancer market is expected to maintain its strong growth trajectory in upcoming years.
• The market for epithelial ovarian cancer is set to experience robust growth in the coming years, escalating to $4.41 billion in 2029, with a compound annual growth rate (CAGR) of 16.1%.
The anticipated increase in market size during the projection period is a result of numerous factors including a surge in ovarian cancer cases, an aging population demographic, heightened awareness about ovarian cancer, an escalation in research funding for cancer, and growing governmental initiatives in the fight against cancer. Key trends projected for the future include advancements in medical imaging technology, the inception of novel molecular diagnostic instruments, cooperation among pharmaceutical corporations, the swift incorporation of artificial intelligence and machine learning in diagnostic procedures, and the broadening application of robotic surgeries.
What Are The Key Drivers Fueling Growth In The Epithelial Ovarian Cancer Market?
The anticipated rise in ovarian cancer cases is set to stimulate the expansion of the epithelial ovarian cancer market. This type of cancer, which primarily impacts the epithelial cells covering the ovaries' surface, seems to be more prevalent due to an aging population, increased awareness, higher detection rates, genetic factors, and lifestyle choices. To effectively combat the most prevalent and aggressive form of ovarian cancer, epithelial ovarian cancer treatment targets malignant cells to enhance survival rates and patient experiences. For example, as reported by the World Ovarian Cancer Coalition, a non-profit organization based in Canada, by 2050, the global figure for women diagnosed with ovarian cancer is projected to rise over 55%, to reach 503,448. Annual fatalities resulting from ovarian cancer are expected to escalate to 350,956, identifying an almost 70% increase from 2022. Hence, the escalating prevalence of ovarian cancer is expected to propel the growth of the epithelial ovarian cancer market.
What Are The Main Segments Of The Global Epithelial Ovarian Cancer Market?
The epithelial ovarian cancer market covered in this report is segmented –
1) By Type Of Treatment: Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Surgery
2) By Drug Class: Platinum-based Chemotherapy Drugs, Poly(ADP-ribose) Polymerase Inhibitors, Bevacizumab, Chemotherapeutic Agents
3) By Stage Of Cancer: Early Stage, Advanced Stage
4) By Diagnosis Method: Imaging, Biopsy, Blood Tests
5) By End User: Hospitals, Clinics, Diagnostic Laboratories
Subsegments:
1) By Chemotherapy: Platinum-Based Chemotherapy, Non-Platinum Chemotherapy, Combination Chemotherapy
2) By Targeted Therapy: Monoclonal Antibodies, PARP Inhibitors, Angiogenesis Inhibitors, Other Targeted Agents
3) By Immunotherapy: Checkpoint Inhibitors, Cancer Vaccines, Adoptive T-Cell Therapy
4) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Progestins
5) By Surgery: Debulking Surgery, Oophorectomy, Hysterectomy, Other Surgical Procedures
Pre-Book The Epithelial Ovarian Cancer Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Epithelial Ovarian Cancer Market?
Leading firms in the epithelial ovarian cancer market are concentrating on the creation of innovative treatments, such as FRa-directed antibody-drug conjugates (ADCs). These are designed to specifically attack cancer cells overexpressing the folate receptor-alpha while limiting damage to healthy cells. An ADC targeting FRa is a specialized cancer treatment that attaches a cytotoxic drug to an antibody that recognizes the folate receptor-alpha (FRa), delivering the drug right to the cancer cells that express this receptor. For example, in November 2024, AbbVie Inc., an American biopharmaceutical firm, received approval from the European Commission for ELAHERE (mirvetuximab soravtansine). This is a targeted therapy for adult patients suffering from platinum-resistant, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer that tests positive for the folate receptor-alpha (FRa). ELAHERE represents a fresh and effective treatment for patients who have undergone up to three prior systemic regimens. It targets a biomarker present in roughly one-third of ovarian cancer patients, increasing survival probability and enhancing life quality. The approval also includes a companion diagnostic to pinpoint suitable patients.
Who Are the Key Players in the Epithelial Ovarian Cancer Market?
Major companies operating in the epithelial ovarian cancer market are include:
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• F. Hoffmann-La Roche AG
• Merck & Co. Inc.
• AbbVie Inc.
• Bayer AG
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• GlaxoSmithKline plc
• Eli Lilly and Company
• Boehringer Ingelheim GmbH
• Merck KGaA
• Siemens Healthineers AG
• Quest Diagnostics Incorporated
• Eisai Co. Ltd.
• Genentech Inc.
• Qiagen N.V.
• Myriad Genetics Inc.
• Zymeworks Inc.
• Novogen Limited
• Karyopharm Therapeutics Inc.
• Clovis Oncology Inc.
• ImmunoGen Inc.
• Fujirebio Diagnostics Inc.
• Vivesto AB
What Is The Most Dominant Region In The Epithelial Ovarian Cancer Market?
North America was the largest region in the epithelial ovarian cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epithelial ovarian cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
